Batten Disease: Clinical Trials

8 trials for Batten Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting, 1 not yet recruiting. 8 Phase 2, 6 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Active not recruiting 1, Not yet recruiting 1
Phase 16Completed 4, Active not recruiting 1, Not yet recruiting 1
Phase 31Completed 1

Follow Batten Disease: new trials by email Literature Review of Batten Disease trials Research Report on Batten Disease

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gene Therapy Trial for CLN6 Batten Disease
scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes) - CLN6, Batten Disease
Phase 1 / Phase 2Not yet recruitingThe Charlotte and Gwenyth Gray Foundation122026-08-012026-05-14
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease
Miglustat 100 milligrams (mg) Oral Capsule - Batten Disease
Phase 1 / Phase 2CompletedBeyond Batten Disease Foundation62022-03-102025-09-09
Gene Therapy for Children With CLN3 Batten Disease
Low dose CLN-301, High dose CLN-301 - CLN3, Batten Disease
Phase 1 / Phase 2Active not recruitingNeela Therapeutics72018-11-132026-06-10
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1), Intracerebroventricular access device - Jansky-Bielschowsky Disease, Batten Disease
Phase 2CompletedBioMarin Pharmaceutical142016-01-222025-02-17
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
BMN 190, Intracerebroventricular (ICV) access device - Jansky-Bielschowsky Disease, Batten Disease
Phase 1 / Phase 2CompletedBioMarin Pharmaceutical232015-02-012022-08-24
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
BMN 190 - Jansky-Bielschowsky Disease, Batten Disease
Phase 1 / Phase 2CompletedBioMarin Pharmaceutical242013-09-012019-03-08
AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis
AAVrh.10CUCLN2 - Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Phase 1 / Phase 2CompletedWeill Medical College of Cornell University82010-04-152020-08-31
Stem Cell Transplant for Inborn Errors of Metabolism
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin - Adrenoleukodystrophy, Metachromatic Leukodystrophy
Phase 2 / Phase 3CompletedMasonic Cancer Center, University of Minnesota1351995-01-012017-12-28

Narrower conditions

Neuronal Ceroid-Lipofuscinoses (8)  ·  Adrenoleukodystrophy (1)  ·  Fucosidosis (1)  ·  Gangliosidosis, GM1 (1)  ·  Gaucher Disease (1)  ·  Leukodystrophy, Globoid Cell (1)  ·  Leukodystrophy, Metachromatic (1)  ·  Niemann-Pick Diseases (1)  ·  Sandhoff Disease (1)  ·  Tay-Sachs Disease (1)  ·  Wolman Disease (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Genetic Diseases, Inborn (8)  ·  Heredodegenerative Disorders, Nervous System (8)  ·  Lipid Metabolism Disorders (8)  ·  Lipid Metabolism, Inborn Errors (8)  ·  Lipidoses (8)  ·  Metabolic Diseases (8)  ·  Metabolism, Inborn Errors (8)  ·  Nervous System Diseases (8)  ·  Neurodegenerative Diseases (8)  ·  Nutritional and Metabolic Diseases (8)  ·  Adrenal Gland Diseases (1)  ·  Adrenal Insufficiency (1)  ·  Brain Diseases (1)  ·  Brain Diseases, Metabolic (1)

Interventions

cerliponase alfa (3)  ·  Antilymphocyte Serum (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Stem Cell Transplantation (1)

Sponsors

BioMarin Pharmaceutical (3)  ·  Beyond Batten Disease Foundation (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Neela Therapeutics (1)  ·  The Charlotte and Gwenyth Gray Foundation (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (8)  ·  Germany (3)  ·  Italy (3)  ·  United Kingdom (3)

Top investigators

An N. Dang Do, MD, PhD (1)  ·  David Jacoby (1)  ·  Gary D. Clark, MD (1)  ·  Kathrin C Meyer, PhD (1)  ·  Paul Orchard, MD (1)  ·  Ronald Crystal, MD (1)

Results publications

PMID 29688815, PMID 33980287, PMID 38101904, PMID 38776275, PMID 21586746, PMID 37035740, PMID 37171121